(Q44854391)

6 December 2017

title

Evolution of hepatitis B virus precore/basal core promoter gene in HBeAg-positive chronic hepatitis B patients receiving lamivudine therapy (English)

1 reference

6 December 2017

1 reference

1 reference

1 reference

Chih-Lin Lin

1

1 reference

6 December 2017

Li-Ying Liao

2

1 reference

6 December 2017

Chaur-Shine Wang

3

1 reference

6 December 2017

Pei-Jer Chen

4

1 reference

6 December 2017

Ming-Yang Lai

5

1 reference

6 December 2017

Ding-Shinn Chen

6

1 reference

6 December 2017

Jia-Horng Kao

7

1 reference

6 December 2017

publication date

1 February 2004

1 reference

6 December 2017

1 reference

6 December 2017

volume

24

1 reference

6 December 2017

issue

1

1 reference

6 December 2017

page(s)

9-15

1 reference

Global control of hepatitis B virus infection.

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.00893.X

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.00893.X

Hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.00893.X

Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.00893.X

Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.00893.X

Real-time PCR for detection and quantitation of hepatitis B virus DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.00893.X

Prevalence of hepatitis C virus infection in patients with antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.00893.X

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.00893.X

Precore and core promoter mutations, hepatitis B virus DNA levels and progressive liver injury in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.00893.X

A case-control study for early prediction of hepatitis B e antigen seroconversion by hepatitis B virus DNA levels and mutations in the precore region and core promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.00893.X

Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.00893.X

Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.00893.X

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.00893.X

Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia-Pacific region. Core Working Party for Asia-Pacific Consensus on Hepatitis B and C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.00893.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.00893.X

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.00893.X

Persistence of viral replication after anti-HBe seroconversion during antiviral therapy for chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2004.00893.X

10.1111/J.1478-3231.2004.00893.X

21 January 2018

Identifiers

DOI

1 reference

6 December 2017

1 reference